Comprehensive Human Respiratory Organoid Technology Platform

Traditional biomedical research frequently uses 2D cell cultures and animal models, which inadequately represent the complexity of human tissues, especially in the respiratory tract. This limitation hampers the development of effective treatments for respiratory diseases. BiomOrgan offers a more realistic in vitro model of the human respiratory system, addressing the shortcomings of conventional methods in drug development.

• Organoids enable scientists to study most in vivo biological processes in culture plates, representing a major breakthrough in biotechnology and biomedical research.
• CVVT and BiomOrgan have developed a proprietary respiratory organoid platform, which allows for the in vitro reconstruction and expansion of entire respiratory epithelial structures, including nasal mucosa, airways, and alveolar organoids.

• The established respiratory organoids demonstrate high efficiency and stability, with a near-perfect success rate. They are easily handled and cultured in serum-free media.
• The technology enables the creation of disease models that enhance drug efficacy and safety testing, ultimately improving patient outcomes.

• The Gold Medal at the 50th Geneva International Exhibition of Inventions in 2025: Applications of propriety respiratory organoids
• The Gold Medal at the 48th Geneva International Exhibition of Inventions in 2023: The respiratory organoid culture system

• Disease Modeling: Accurately mimic the human respiratory system to study diseases like COVID-19, providing a more realistic model than traditional cell lines.
• Drug Development: Evaluates drug efficacy, toxicity, and optimal delivery methods to respiratory tissues, streamlining the development process and improving safety.
• Precision Medicine: Develop personalized treatments based on individual patient responses to drugs and disease progression, improving patient outcomes.
• Host-microbe Interaction: Investigate the complex interactions between the respiratory system and pathogens, providing insights into infection and immunity.

• Mature airway organoids, methods of making and uses thereof (Patent application No.: CN 201980037552.0A; US 17/059,965; EP19812157.6)
• Alveolar organoids, methods of making and uses thereof (Patent application No.: CN202280058457.0A; US 17/059,965)
• Human nasal organoids and methods of making and methods of use thereof (Patent application No.: CN 202380051888.9; US 18/881,591)
• A System and Composition of Respiratory Organoids for Propagation of Viruses and Methods Thereof (Patent application No.: CN 202510137326.7; US 19/046,894; EP 25156715.2)